Status:
COMPLETED
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Bladder Urothelial Carcinoma In Situ
Recurrent Bladder Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial studies the safety and feasibility of utilizing acupuncture in patients with high-risk bladder cancer that has not spread to the surrounding muscle (non-muscle invasive) undergoing...
Detailed Description
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable...
Eligibility Criteria
Inclusion
- English-speaking
- Diagnosis of American Urological Association (AUA) high-risk non-muscle invasive bladder cancer (NMIBC), including high grade (HG) pT1 (invading only the lamina propria of the bladder), recurrent HG pTa (superficial tumors), HG pTa \> 3 cm in size or multifocal, any carcinoma in situ, any variant histology, any lymphovascular invasion, and HG prostatic urethral involvement
- Diagnosis with urothelial carcinoma (primary histologic subtype), localized to the bladder, in the absence of nodal or other visceral metastases
- Patients who have been indicated for induction intravesical BCG in shared-decision-making with their primary urologist
- Have not received acupuncture in the previous 3 months
- Access to phone for study contacts
- Willing and able to participate in trial activities
- Platelets: 20,000/ uL or greater
- Absolute neutrophil count (ANC): 500 cells/uL or greater
- Able to understand and willing to sign written informed consent in English
Exclusion
- Subjects who have had intravesical or systemic chemotherapy or radiation therapy for bladder cancer or for other malignancies prior to entering the study
- Subjects who are indicated to receive other intravesical agents or therapies concurrently with BCG will be excluded
- Subjects who have muscle-invasive bladder cancer, radiographic evidence of lymph node metastases or metastatic disease involving other organs including brain metastases
- Patients with predominant histology other than urothelial carcinoma of the bladder who would not otherwise be considered candidates for BCG
- BCG is contraindicated in:
- Patients who are pregnant or lactating
- Patients with active tuberculosis
- Immunosuppressed patients with congenital or acquired immune deficiency, whether due to concurrent disease (e.g. acquired immunodeficiency syndrome \[AIDS\], lymphoma, leukemia), concomitant cancer therapy (cytotoxic drugs, radiation), or immunosuppressive therapy (e.g. corticosteroids, disease-modifying anti-rheumatic drugs \[DMARDs\])
- Symptomatic urinary tract infection
- Febrile illness
- Patients requiring chronic treatment with certain antibiotics that may interfere with the effectiveness of BCG
- Any previous allergies or severe reactions to BCG
- Not pregnant or trying to become pregnant. Acupuncture points included in the protocol are contraindicated with pregnancy
- Does not have a pacemaker. There is potential of electrostimulation interfering with the operation and function of pacemakers
- Patients requiring chronic treatment with certain antibiotics that may interfere with the effectiveness of BCG. Fluoroquinolone therapy may decrease the efficacy of intravesical BCG. Antibiotic therapy for ongoing treatment of active tuberculosis will decrease the efficacy of intravesical BCG
- Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded. Acupuncture points included in the protocol are contraindicated with pregnancy and BCG is contraindicated in pregnancy
- Pacemaker. Patients with pacemakers are restricted due to the potential of electrostimulation interfering with a pacemakers operation
- Platelets: \< 20,000/ uL. Risk of bleeding with acupuncture
- ANC: \< 500 cells/uL. Risk of infection with acupuncture
- Received acupuncture in the previous 3 months. Acupuncture treatment effects persist after a course of treatment, previous exposure to the intervention has the potential to affect the baseline data for treatment and control arms
Key Trial Info
Start Date :
January 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04496219
Start Date
January 22 2021
End Date
August 23 2022
Last Update
January 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109